Introduction
Flunarizine Dihydrochloride is a long-acting, orally active diphenylpiperazine calcium channel blocker (CCB) with additional antihistaminic, anti-serotonergic and mild anticholinergic properties. It is a core pharmaceutical raw material for the clinical prevention of migraine and treatment of vestibular vertigo, and is widely used as an adjuvant for cerebrovascular insufficiency-related symptoms. Its chemical formula is C₂₆H₂₈F₂N₂·2HCl, and it is clinically formulated into oral tablets and hard capsules of standard specifications (5 mg, 10 mg) for individualized dosing in adults and children. Characterized by high oral bioavailability (~80%), rapid absorption (unaffected by food intake), an extremely long elimination half-life (≈20 days) due to extensive tissue distribution, and hepatic metabolism with biliary excretion, it exerts sustained therapeutic effects with once-daily administration (usually at bedtime). As a cerebrovascular-selective CCB, it has minimal effects on systemic peripheral blood vessels and the heart, avoiding significant hypotension or cardiac conduction disturbances—its key clinical advantage over non-selective CCBs. It is widely used in neurology, otorhinolaryngology, and general medicine for migraine prophylaxis, vertigo management, and cerebrovascular disease adjuvant therapy, with definite efficacy, good tolerability at recommended doses, and simple administration.
Core Pharmacological Mechanism (to support its therapeutic uses)
Flunarizine Dihydrochloride exerts its multi-faceted therapeutic effects through a combination of calcium channel blockade and receptor antagonism, with high selectivity for the cerebrovascular system and vestibular apparatus—this selectivity underpins its clinical indications for migraine and vertigo, and minimizes systemic adverse reactions. Its core pharmacological actions are as follows:
Selective cerebrovascular calcium channel blockade: It reversibly blocks L-type voltage-gated calcium channels on the cell membranes of cerebral vascular smooth muscle cells, inhibiting pathological extracellular calcium ion influx into cells. This relaxes spastic cerebral blood vessels, normalizes abnormal cerebral vascular tone, and improves cerebral blood flow and microcirculation—especially in the ischemic or hypoperfused brain regions associated with migraine and cerebrovascular insufficiency. It also prevents vasoconstriction induced by vasoactive substances (e.g., serotonin, histamine) that trigger migraine attacks, and reduces cerebral vascular hyperreactivity to various stimuli.
Vestibular system modulation: It blocks calcium channels in the vestibular hair cells and vestibular nucleus in the brainstem, inhibiting abnormal vestibular nerve impulses and reducing the excitability of the vestibular-ocular reflex. Additionally, it exerts a competitive antagonistic effect on histamine H1 receptors in the vestibular apparatus and inner ear, directly relieving vestibular dysfunction-induced vertigo, nystagmus, and motion sickness. This dual action on calcium channels and H1 receptors makes it highly effective for both peripheral and central vertigo.
Neuronal protective effect: It inhibits calcium overload in cerebral neurons caused by ischemia, hypoxia, or excitatory amino acid release, reducing neuronal damage and apoptosis. This protective effect improves neurological function in patients with cerebrovascular insufficiency (e.g., cerebral arteriosclerosis) and reduces the risk of recurrent cerebral ischemic events as an adjuvant therapy.
Mild additional receptor effects: It has weak antagonistic effects on serotonin 5-HT2 receptors and dopamine D2 receptors, and mild anticholinergic activity. The anti-serotonergic effect further prevents migraine-triggering vasoconstriction, while the mild dopamine blockade may contribute to rare extrapyramidal adverse reactions with long-term high-dose use (a key clinical caution).
Notably, flunarizine dihydrochloride has no significant effect on systemic blood pressure or cardiac function at therapeutic doses, as it does not block calcium channels in peripheral vascular smooth muscle or cardiac myocytes—this differentiates it from cardiovascular CCBs (e.g., amlodipine) and makes it safe for patients with normal or low blood pressure.
Primary Therapeutic Uses
Flunarizine Dihydrochloride is clinically indicated as a first-line agent for the prophylactic treatment of migraine in adults and children (≥6 years old) and the symptomatic treatment of various vestibular vertigo; it is also used as an adjuvant for cerebrovascular insufficiency and related neurological symptoms, and for the management of idiopathic tinnitus. It is a prophylactic drug (not for acute attack relief) for migraine, and its vertigo treatment efficacy covers both peripheral and central etiologies—its main clinical advantages. Its specific clinical applications are as follows:
1. Prophylactic Treatment of Migraine
It is the first-line oral prophylactic drug for frequent recurrent migraine (≥2 attacks per month) and migraine with aura in adults and children (≥6 years old), and is also effective for chronic migraine (≥15 headache days per month with migraine features). It is not indicated for the acute relief of migraine attacks (analgesics or triptans are first-line for acute use). Prophylactic use reduces the frequency, severity, and duration of migraine attacks, decreases the need for acute migraine medications, and improves the quality of life of patients with refractory migraine. It is particularly suitable for migraine patients who cannot tolerate or have contraindications to other prophylactic drugs (e.g., beta-blockers, tricyclic antidepressants), and for pediatric migraine (a population with limited prophylactic treatment options). The therapeutic effect usually begins 2–4 weeks after the start of treatment, with the maximum effect achieved at 8–12 weeks.
2. Treatment of Vestibular Vertigo (Peripheral and Central)
It is a core therapeutic agent for the symptomatic relief of various acute and chronic vertigo caused by vestibular dysfunction, covering both peripheral vertigo (the majority of clinical cases) and central vertigo, with rapid onset of action (1–3 days) for acute vertigo and sustained efficacy for chronic vertigo. Specific indications include:
Peripheral vertigo: Meniere’s disease, vestibular neuritis, benign paroxysmal positional vertigo (BPPV, adjuvant therapy after repositioning maneuvers), labyrinthitis, and motion sickness-induced vertigo/nausea; it effectively relieves vertigo, dizziness, tinnitus, and ear fullness associated with these conditions.
Central vertigo: Vertigo caused by cerebrovascular diseases (cerebral arteriosclerosis, vertebrobasilar artery insufficiency, cerebral infarction in the posterior circulation), vestibular migraine, multiple sclerosis, and brainstem lesions; it improves cerebral blood flow to the vestibular nucleus and modulates abnormal vestibular impulses to relieve central vertigo.
It is also the preferred drug for intractable vertigo that cannot be controlled by antihistamines or anticholinergics alone, due to its dual mechanism of vestibular modulation and cerebrovascular improvement.
3. Adjuvant Treatment of Cerebrovascular Insufficiency
It is used as an adjuvant drug for chronic cerebral arteriosclerosis, vertebrobasilar artery insufficiency, and the recovery phase of cerebral infarction (especially posterior circulation infarction), improving cerebral microcirculation and relieving neurological symptoms caused by cerebral blood flow hypoperfusion: frequent headache, dizziness, lightheadedness, limb numbness, hypoesthesia, memory impairment, and poor concentration. It is not a first-line etiological treatment for cerebrovascular diseases (antiplatelet, lipid-lowering drugs are first-line) but a symptomatic adjuvant that enhances neurological function recovery and reduces the frequency of ischemic symptom exacerbations.
4. Adjuvant Treatment of Idiopathic Tinnitus
It is used for the symptomatic treatment of unilateral or bilateral idiopathic tinnitus (excluding tinnitus caused by ear trauma, infection, or tumor) with a frequency of ≥4 kHz, especially tinnitus associated with cerebral blood flow insufficiency or vestibular dysfunction. It improves inner ear and cochlear blood flow by relaxing cerebral and inner ear blood vessels, and reduces the excitability of the auditory nerve, thereby alleviating tinnitus severity and improving patients’ sleep and daily life affected by tinnitus.
5. Pediatric Clinical Applications (≥6 years old)
It is the most widely used oral drug for pediatric migraine prophylaxis and vertigo treatment (e.g., vestibular neuritis, motion sickness), with age-adapted low-dose administration and good tolerability. The cerebrovascular selectivity and lack of systemic hypotensive effects make it safe for children, and it effectively reduces the impact of migraine and vertigo on pediatric school performance and daily activities.
Clinical Application Key Points
Flunarizine Dihydrochloride features simple once-daily administration and good overall tolerability, but its clinical use requires strict differentiation between prophylaxis and acute treatment (not for migraine acute attacks), and cautious long-term use to avoid extrapyramidal adverse reactions (especially in the elderly and children). Key application points for administration, dosage, safety, and drug compatibility are as follows:
1. Administration and Dosage
Oral administration, once daily at bedtime (the optimal time to minimize daytime drowsiness, the most common adverse reaction); can be taken with or without food (food has no effect on absorption or efficacy). Tablets/capsules are swallowed whole with water, and individualized dosing is based on indication, age, and patient tolerability. No dose adjustment is required for mild to moderate hepatic/renal insufficiency (the drug is mainly metabolized in the liver and excreted in bile, with minimal renal excretion):
Adult Migraine Prophylaxis: Initial dose = 10 mg once daily (bedtime); reduce to 5 mg once daily if adverse reactions (e.g., severe drowsiness) occur; the maintenance dose is 5–10 mg/day, with a course of 3–6 months (evaluate efficacy after 3 months; discontinue if no effect).
Adult Vertigo/Tinnitus/Cerebrovascular Insufficiency: 10–20 mg once daily (bedtime) for acute symptoms; reduce to 5–10 mg once daily for chronic maintenance treatment after symptom relief.
Pediatric (6–14 years old) Migraine Prophylaxis/Vertigo: 5 mg once daily (bedtime) (the maximum pediatric dose); adjust to every other day 5 mg if drowsiness occurs; the course of migraine prophylaxis is 2–3 months.
Elderly Patients (≥65 years old): Initial dose = 5 mg once daily (bedtime); titrate to 10 mg once daily only if symptoms are not relieved, and close monitoring for extrapyramidal symptoms is required (higher susceptibility).
Key Note: For migraine prophylaxis, discontinue the drug immediately if no significant efficacy is observed after 3 months of treatment; long-term continuous use (＞6 months) is not recommended unless strictly necessary, to reduce the risk of adverse reactions.
2. Main Adverse Reactions
Adverse reactions are mild, transient, and dose-related in most patients, mostly appearing in the first 1–2 weeks of treatment and resolving spontaneously with continued administration or dose reduction; the overall incidence is <10%. Severe adverse reactions are rare and mostly associated with long-term high-dose use or use in high-risk populations (the elderly, children). Adverse reactions are mainly divided into central nervous system (CNS) effects, gastrointestinal effects, and rare extrapyramidal reactions:
Most Common (incidence 5–10%): CNS depression (drowsiness, fatigue, lethargy)—the most frequent reaction, significantly reduced by bedtime administration; mild gastrointestinal symptoms (nausea, abdominal discomfort, dry mouth); weight gain (mild, due to increased appetite, reversible after drug withdrawal).
Less Common (incidence 1–5%): Dizziness, headache, insomnia (rare, in individual patients), skin rash, pruritus, and transient hypotension (extremely mild, no clinical significance).
Rare Severe Adverse Reactions (incidence <1%): Extrapyramidal symptoms (bradykinesia, rigidity, tremor, akathisia)—mostly in elderly patients with long-term (＞6 months) high-dose use, reversible after immediate drug withdrawal; depressive symptoms (in patients with a history of depression); elevated hepatic transaminases (mild, reversible after withdrawal); galactorrhea (rare, due to mild dopamine blockade).
Long-term use (＞12 months) may increase the risk of chronic extrapyramidal reactions, especially in the elderly; regular clinical re-evaluation is mandatory for long-term treatment.
3. Contraindications
Flunarizine Dihydrochloride is contraindicated in patients with:
Hypersensitivity to flunarizine dihydrochloride, other diphenylpiperazine derivatives, or any component of the pharmaceutical preparation;
A history of depressive disorder (the drug may exacerbate depressive symptoms);
Parkinson’s disease or other extrapyramidal system diseases (the drug may worsen motor symptoms);
Severe hepatic insufficiency (Child-Pugh C grade, with no dose adjustment guidance and increased risk of drug accumulation).
4. Key Precautions
Not for acute migraine/vertigo attacks: It is a prophylactic and chronic symptomatic treatment drug; it has no rapid analgesic or anti-vertigo effect for acute migraine attacks (use triptans, non-steroidal analgesics) or acute severe vertigo (use intravenous vestibular suppressants); do not increase the dose for acute symptoms, as this only increases adverse reactions.
Extrapyramidal symptom monitoring: Closely monitor for motor symptoms (tremor, rigidity, slow movement) in elderly patients, children, and long-term users; discontinue the drug immediately if such symptoms occur—most resolve within 1–2 weeks of withdrawal. Avoid long-term high-dose use (＞6 months) unless efficacy is proven essential.
Depression monitoring: Evaluate mood status before treatment; discontinue the drug at the first sign of depressive symptoms (low mood, anhedonia, suicidal ideation) during treatment, especially in patients with a personal or family history of depression.
Driving and operating machinery: Drowsiness and fatigue are common initial adverse reactions; avoid engaging in high-risk activities (driving, operating heavy machinery) until the body adapts to the drug (usually 2–4 weeks). Bedtime administration is the most effective way to minimize this risk.
Pregnancy and lactation: Use only when the therapeutic benefit outweighs the potential fetal/infant risk (limited human safety data; animal studies show no teratogenic effects). The drug crosses the placental barrier and is excreted in breast milk; breastfeeding is not recommended during treatment to avoid potential CNS depression in infants.
Weight gain management: Advise patients to monitor body weight during treatment; reduce calorie intake and increase physical activity if mild weight gain occurs—weight gain is reversible after drug withdrawal.
Hepatic/renal insufficiency: No dose adjustment for mild to moderate hepatic/renal insufficiency; use with extreme caution in severe hepatic insufficiency (no clinical data) and discontinue if liver function abnormalities occur.
Abrupt withdrawal: No severe withdrawal symptoms; gradual dose reduction over 1–2 weeks is recommended for long-term users to avoid transient rebound of migraine or vertigo symptoms (rare).
5. Drug Interactions
Flunarizine Dihydrochloride has a low risk of clinically significant drug interactions due to its selective cerebrovascular action, minimal hepatic metabolism (no induction/inhibition of cytochrome P450 enzymes), and lack of binding to plasma proteins. Most interactions are synergistic CNS depression with other sedative drugs, and minor clinical adjustments are sufficient to manage risks. Key drug interactions are as follows:
CNS depressants (sedatives, hypnotics, anxiolytics): Combined use with benzodiazepines, barbiturates, tricyclic antidepressants, or antipsychotics enhances sedative and drowsy effects; reduce the dose of the concomitant CNS depressant and administer flunarizine at bedtime to minimize risk.
Antihistamines (H1 blockers): Combined use with oral antihistamines (e.g., cetirizine, chlorpheniramine) enhances vestibular suppression and anti-vertigo efficacy, but may increase mild drowsiness—no dose adjustment is required for short-term use (acute vertigo).
Migraine acute treatment drugs: No interaction with triptans (sumatriptan), non-steroidal analgesics (ibuprofen), or ergot alkaloids; safe for combined use (flunarizine for prophylaxis, acute drugs for attack relief).
Anti-Parkinson drugs (levodopa, dopamine agonists): Flunarizine’s mild dopamine D2 blockade may antagonize the efficacy of anti-Parkinson drugs and worsen motor symptoms; combined use is contraindicated in Parkinson’s disease patients (a contraindication for flunarizine use).
Antiepileptic drugs: No significant interaction with antiepileptics (carbamazepine, valproic acid, levetiracetam); flunarizine may have a mild adjuvant anticonvulsant effect, and combined use is safe for epileptic patients with migraine/vertigo.
Cardiovascular drugs (antihypertensives, antiplatelets): No interaction with beta-blockers, ACE inhibitors, ARBs, calcium channel blockers, or antiplatelets (aspirin, clopidogrel); safe for combined use in patients with migraine/vertigo and hypertension/cerebrovascular disease.
Over-the-counter (OTC) drugs: No interaction with antipyretics (acetaminophen), cough suppressants, or cold preparations; avoid OTC drugs containing sedative antihistamines (e.g., diphenhydramine) to prevent excessive drowsiness.
FAQ
Q1. Can I get a free sample?
We can send you a samll free sample, and you only need to pay for the shipping cost.
Q2. What is the HyperChem payment term?
T/T in advance
LC at sight
DP at sight
Bank transfer
PayPal
Bitcoin...
Q3. What is HyperChem shipment policy?
Our policy is to strive for the quickest shipment time possible.
For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.
Q4. What is HyperChem shipment term?
By Express
FedEx UPS DHL EMS
Fast: 3-7 days around, high cost, door to door service
By Air
Suitable for more than 50kg
Fast: 3-7 days, hight cost, port to port, professional broker needed
By Sea
Suitable for more than 500kg
Fast: 7-45 days, low cost, port to port, professional broker needed
We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.
Q5. What HyperChem will provide after shipment?
For sample orders:
After shipment is done, an timely email including:
1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice
For commercial orders:
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.
